These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 12738544)

  • 1. Influence of dorzolamide on corneal endothelium.
    Inoue K; Okugawa K; Oshika T; Amano S
    Jpn J Ophthalmol; 2003; 47(2):129-33. PubMed ID: 12738544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A double-masked, randomized, 1-year study comparing the corneal effects of dorzolamide, timolol, and betaxolol. Dorzolamide Corneal Effects Study Group.
    Lass JH; Khosrof SA; Laurence JK; Horwitz B; Ghosh K; Adamsons I
    Arch Ophthalmol; 1998 Aug; 116(8):1003-10. PubMed ID: 9715679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of dorzolamide on corneal thickness, endothelial cell count and corneal sensibility.
    Kaminski S; Hommer A; Koyuncu D; Biowski R; Barisani T; Baumgartner I
    Acta Ophthalmol Scand; 1998 Feb; 76(1):78-9. PubMed ID: 9541439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Impact of prostaglandin-F(2alpha)-analogues and carbonic anhydrase inhibitors on central corneal thickness -- a cross-sectional study on 403 eyes].
    Viestenz A; Martus P; Schlötzer-Schrehardt U; Langenbucher A; Mardin CY
    Klin Monbl Augenheilkd; 2004 Sep; 221(9):753-6. PubMed ID: 15459842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Four-week safety and efficacy study of dorzolamide, a novel, active topical carbonic anhydrase inhibitor.
    Wilkerson M; Cyrlin M; Lippa EA; Esposito D; Deasy D; Panebianco D; Fazio R; Yablonski M; Shields MB
    Arch Ophthalmol; 1993 Oct; 111(10):1343-50. PubMed ID: 8216014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 2% dorzolamide and cornea: an ultrabiomicroscopic study.
    Uva MG; Russo V; Longo A; Ott JP; Reibaldi A
    Acta Ophthalmol Scand Suppl; 1997; (224):23-4. PubMed ID: 9589715
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of dorzolamide on corneal endothelial function in normal human eyes.
    Egan CA; Hodge DO; McLaren JW; Bourne WM
    Invest Ophthalmol Vis Sci; 1998 Jan; 39(1):23-9. PubMed ID: 9430541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of topical brinzolamide 1% and dorzolamide 2% eye drops given twice daily in addition to timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
    Michaud JE; Friren B;
    Am J Ophthalmol; 2001 Aug; 132(2):235-43. PubMed ID: 11476685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of dorzolamide hydrochloride on central corneal thickness in humans with cornea guttata.
    Wirtitsch MG; Findl O; Heinzl H; Drexler W
    Arch Ophthalmol; 2007 Oct; 125(10):1345-50. PubMed ID: 17923541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical efficacy and safety of brinzolamide (Azopt), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension. Brinzolamide Primary Therapy Study Group.
    Silver LH
    Am J Ophthalmol; 1998 Sep; 126(3):400-8. PubMed ID: 9744373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dorzolamide and corneal recovery from edema in patients with glaucoma or ocular hypertension.
    Giasson CJ; Nguyen TQ; Boisjoly HM; Lesk MR; Amyot M; Charest M
    Am J Ophthalmol; 2000 Feb; 129(2):144-50. PubMed ID: 10682965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Assessment of visual function under treatment with topical antiglaucoma agents and systemic vasodilators. Clinical study on glaucoma patients].
    Popa SA; Bucătariu PM; Azoicăhi D; Costin D; Manole A; Matei M; Merchez M
    Rev Med Chir Soc Med Nat Iasi; 2011; 115(2):455-9. PubMed ID: 21870740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-term effect of dorzolamide hydrochloride on central corneal thickness in humans with cornea guttata.
    Wirtitsch MG; Findl O; Kiss B; Petternel V; Heinzl H; Drexler W
    Arch Ophthalmol; 2003 May; 121(5):621-5. PubMed ID: 12742838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Ocular hemodynamics and visual field in glaucoma treated with dorzolamide].
    Bernd AS; Pillunat LE; Böhm AG; Schmidt KG; Richard G
    Ophthalmologe; 2001 May; 98(5):451-5. PubMed ID: 11402826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Ocular pulse amplitude, intraocular pressure and beta blocker/carbonic anhydrase inhibition in combined therapy of primary open-angle glaucoma].
    Schmidt KG; von Rückmann A; Becker R; Pillunat LE
    Klin Monbl Augenheilkd; 1999 Dec; 215(6):361-6. PubMed ID: 10637801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of systemic acetazolamide and topical dorzolamide in reducing intraocular pressure and aqueous humor formation.
    Rosenberg LF; Krupin T; Tang LQ; Hong PH; Ruderman JM
    Ophthalmology; 1998 Jan; 105(1):88-92; discussion 92-3. PubMed ID: 9442783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brimonidine 0.2% versus dorzolamide 2% each given three times daily to reduce intraocular pressure.
    Stewart WC; Sharpe ED; Harbin TS; Pastor SA; Day DG; Holmes KT; Stewart JA
    Am J Ophthalmol; 2000 Jun; 129(6):723-7. PubMed ID: 10926979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A six-week dose-response study of the ocular hypotensive effect of dorzolamide with a one-year extension. Dorzolamide Dose-Response Study Group.
    Strahlman E; Tipping R; Vogel R
    Am J Ophthalmol; 1996 Aug; 122(2):183-94. PubMed ID: 8694086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the efficacy and safety of latanoprost 0.005% compared to brimonidine 0.2% or dorzolamide 2% when added to a topical beta-adrenergic blocker in patients with primary open-angle glaucoma or ocular hypertension.
    Stewart WC; Sharpe ED; Day DG; Kolker AE; Konstas AG; Lee WH; Rieser JC; Chopra H; Holmes KT
    J Ocul Pharmacol Ther; 2000 Jun; 16(3):251-9. PubMed ID: 10872922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose response and duration of action of dorzolamide, a topical carbonic anhydrase inhibitor.
    Lippa EA; Carlson LE; Ehinger B; Eriksson LO; Finnström K; Holmin C; Nilsson SE; Nyman K; Raitta C; Ringvold A
    Arch Ophthalmol; 1992 Apr; 110(4):495-9. PubMed ID: 1562255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.